Amicus Therapeutics (FOLD)

• Market cap: $1.98B
• 1 day: 8.07%
• 5 days: 4.21%
• 1 month: -4.03%
• 3 months: -34.72%
• 6 months: -33.44%
• Year to date: -30.93%
• 1 year: -32.32%
• 5 years: -49.01%
• 10 years: -41.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Employees: 499

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

4% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 101

2% less call options, than puts

Call options by funds: $4.77M | Put options by funds: $4.87M

7% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 42

1.36% less ownership

Funds ownership: 103.45% [Q3] → 102.09% (-1.36%) [Q4]

2% less funds holding

Funds holding: 287 [Q3] → 282 (-5) [Q4]

12% less capital invested

Capital invested by funds: $3.28B [Q3] → $2.87B (-$403M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $9 40% upside
• Avg. target: $16 149% upside
• High target: $22 242% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

UBS Karl Chalabala 0% 1-year accuracy 0 / 2 met price target	242% upside $22	Buy Maintained	2 May 2025
Goldman Sachs Salveen Richter 27% 1-year accuracy 3 / 11 met price target	40% upside $9	Neutral Maintained	2 May 2025
Wells Fargo Tiago Fauth 31% 1-year accuracy 8 / 26 met price target	164% upside $17	Overweight Maintained	20 Feb 2025